Compare CTSO & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | UG |
|---|---|---|
| Founded | 1997 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 30.8M |
| IPO Year | 2008 | 1995 |
| Metric | CTSO | UG |
|---|---|---|
| Price | $0.41 | $7.37 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | ★ 204.4K | 4.6K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 7.10% |
| EPS Growth | ★ 65.79 | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $22,503,908.00 | $10,545,468.00 |
| Revenue This Year | $10.34 | N/A |
| Revenue Next Year | $22.41 | N/A |
| P/E Ratio | ★ N/A | $36.00 |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.37 | $5.58 |
| 52 Week High | $1.23 | $9.88 |
| Indicator | CTSO | UG |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 65.75 |
| Support Level | $0.37 | $6.86 |
| Resistance Level | $0.73 | $7.43 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 25.67 | 73.02 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.